From cells to purified capsids: How to develop a scalable rAAV process

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room to improve production, purification, and analytics. Here we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a successful process are high overall yields of full capsids with empty capsid reduction and efficient impurity removal.

In this webinar you will learn:

• Common pitfalls for rAAV processing and ways to overcome the challenges
• How the full and empty AAV capsid separation can be significantly improved with one chromatography resin and one protocol for AAV2, AAV5, AAV8 and AAV9

Åsa Hagner McWhirter

Principal Scientist at Cytiva

Åsa has been with Cytiva based in Uppsala, Sweden since 2003 and is a downstream and analytics SME, with a broad and deep understanding of viral vector processing. Due to her long experience and from customer interactions she has gained insights into common challenges and pitfalls in the area of viral vectors and vaccines as well as general protein purification and analysis. She has also worked with proteomics and fluorescent-based protein analysis technologies.

Åsa holds a PhD in Medical Biochemistry from Uppsala University in 1999 based on research around biosynthesis of proteoglycans. The studies involved polysaccharide structure analysis, enzyme purification and cloning as well as characterizing an enzyme reaction.

Watch now

SPEAKERS

Åsa Hagner McWhirter

Principal Scientist at Cytiva

You might also like

How to build an AAV platform that produces higher titers and percent full capsids

Leisha Kopp, Chris Brown

1 May

Watch

How to use AI and machine learning in cell therapy process development

Alex Sargent

13 November

Watch

From process development to manufacturing: how to successfully optimize and scale up the AAV enrichment step on novel CIMmultus QA HR line

Rok Žigon, Maja Leskovec

16 May

Watch

Integrated plasmid engineering and manufacturing process: a unified approach from lab to clinic

Pauline Vieugué, PhD, Philippe Ledent, PhD

24 April

Watch

Pairing a novel enhancer with transfection reagents to enable high-titer rAAV production

F Dziopa, R Gantier, B Reese

28 November 2023

Watch